ClinicalTrials.gg
Not yet recruitingNCT07662863SPARE-UC-01Updated Jun 23, 2026

Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)

A Phase 2 interventional study of Sacituzumab Tirumotecan and MMAE-based ADC in Bladder Cancer, Metastatic Urothelial Carcinoma and Urothelial Carcinoma, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Urinary Bladder Neoplasms with a site in China — 102 open to participants now, 119 under way, 17 of them phase 3. Urinary Bladder Neoplasms · China.

Planned enrollment
71st of 141
75 · median 75
Started
2026
with 24 others
Phase 2
40 of 194
22 open now
Primary completion
2028-12
later than 93 of 118 live
Registered
179th of 194
by date
Lead sponsor
5 of 194
Fudan University

Among the 194 studies in Urinary Bladder Neoplasms with a site in China, this one is the 71st largest by planned enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2026, is one of 40 in phase 2, reaches primary completion later than 93 of the 118 other live ones, and was the 179th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

102 of the 194 studies in Urinary Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Urinary Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

The main goal of this clinical trial is to learn if a new targeted cancer drug called sacituzumab tirumotecan (sac-TMT) works to treat cancer while causing less nerve damage in patients with advanced urothelial carcinoma who have progressed on or could not tolerate previous treatment such as enfortumab vedotin plus pembrolizumab (EVP) or disitamab vedotin plus toripalimab (DVT).

The main question it aims to answer is: Does sac-TMT lower the risk of getting severe nerve damage, as measured together by doctors, machines, and the participants?

Researchers will compare sac-TMT to alternative MMAE-based ADC drugs (switching to a different MMAE-based ADC after the first one stopped working) to see if sac-TMT causes less nerve damage while still effectively treating the cancer. A small group of participants who had to stop their previous MMAE-based ADC treatment because of nerve damage will also receive sac-TMT to learn if the drug is safe for their nerves.

Participants will:

  1. Receive either sac-TMT or another MMAE-based ADC drug
  2. Have regular physical exams by a doctor to check their nerves
  3. Have machine tests to measure how well their nerves work
  4. Answer survey questions about their pain, numbness, and daily activities
Read the detailed description

Metastatic urothelial carcinoma (mUC) is associated with a poor prognosis, and traditional platinum-based chemotherapy offers limited clinical benefit with significant toxicity. In recent years, the emergence of antibody-drug conjugates (ADCs) has transformed the treatment landscape of mUC. Nectin-4-directed enfortumab vedotin (EV) and HER2-directed disitamab vedotin (DV) have demonstrated breakthrough survival benefits in multiple pivotal clinical studies. EV plus pembrolizumab (EVP) and DV plus toripalimab (DVT) have been approved and are increasingly adopted as first-line treatments for mUC, with growing utilization in Chinese clinical practice.

However, as patient survival extends, the long-term safety profile of ADCs has become a major clinical challenge. Both EV and DV utilize MMAE as their cytotoxic payload, a potent microtubule- targeting agent. Non-specific uptake of these ADCs may lead to the release of MMAE within peripheral nerves, potentially causing microtubule dysregulation. By interfering with microtubule dynamics and inhibiting microtubule-dependent axonal transport, MMAE is thought to contribute to the development of peripheral neuropathy. Clinical data indicate that EV and DV cause a high incidence of peripheral neuropathy. Numbness, pain, and motor dysfunction significantly impair patients' activities of daily living (ADLs). Given the absence of effective prophylactic or therapeutic agents for peripheral neuropathy, clinical management is currently limited to dose reductions or complete treatment discontinuation, which will inevitably diminish anti-tumor efficacy.

Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC delivering a topoisomerase I (Topo-I) inhibitor payload. This payload induces DNA double-strand breaks within the cell nucleus, completely avoiding interference with the cytoskeletal microtubule system. This mechanistic difference fundamentally eliminates the biological basis for axonal transport blockade. Preliminary data from the Phase 1/2 MK-2870-001/KL264-01 study showed that sac-TMT achieved an overall objective response rate (ORR) of 31% and a median overall survival (OS) of 12.1 months in previously treated mUC patients, demonstrating a favorable efficacy profile. Notably, no typical drug-related peripheral neurotoxicity events were observed, highlighting a neuroprotective advantage.

The SPARE-UC-01 study is a head-to-head, Phase II clinical trial to compare the neurotoxicity and anti-tumor efficacy of sac-TMT versus sequential MMAE-based ADC therapy. The study targets a population that has progressed on or is intolerant to prior EVP or DVT. By comparing sac-TMT to the sequential use of alternative MMAE-based ADCs, the research aims to provide an evidence-based sequential treatment strategy. The study utilizes an integrated evaluation system designed to quantitatively capture the spectrum of neurotoxicity. This includes investigator-assessed NCI-CTCAE v5.0 scoring of Peripheral Neuropathy Progression Rate (PNPR), instrument-based nerve conduction studies (NCS), and patient- reported quality-of-life outcomes (PROs). Such a three-dimensional paradigm ensures that both structural nerve damage and functional disability are accurately documented. In view of the substantial population of patients who undergo discontinuation of MMAE-ADCs due to cumulative neurotoxicity, an observational cohort has been established within this study. This cohort aims to characterize the clinical utility of sac-TMT in these patients. Given that its payload does not target the microtubule system, sac-TMT is expected to provide effective treatment without introducing additional neurotoxicity.

03

Conditions studied

  • Bladder Cancer
  • Metastatic Urothelial Carcinoma
  • Urothelial Carcinoma
  • Peripheral Neuropathy

Keywords

  • Peripheral Neuropathy
  • Sacituzumab Tirumotecan
  • Enfortumab Vedotin
  • MMAE
  • Disitamab Vedotin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must voluntarily sign the written Institutional Review Board (IRB)/Ethics Committee (EC) approved form (ICF) prior to any screening procedures.
  2. Age > 18 years at the time of signing the ICF.
  3. or cytologically confirmed locally advanced (unresectable) or urothelial carcinoma (UC), including bladder, ureter, renal pelvis, or urethra. Participants with mixed histology are eligible provided that UC is the predominant component (> 50%).
  4. Must have received at least one for locally advanced or metastatic UC (e.g., Enfortumab Vedotin plus Pembrolizumab, Disitamab Vedotin plus Toripalimab, platinum-based chemotherapy, , Nectin-4 ADCs, ADCs, FGFR inhibitors, or other palliative chemotherapy regimens).
  5. Neuropathy Status:

    Cohort A/B: Baseline peripheral neuropathy (PN) Grade 0-1 (per v5.0) with stable nerve function confirmed by Nerve Conduction Study (NCS) during screening.

    Cohort C (Observational): Baseline PN Grade 2, or a history of PN > Grade 2 where the investigator deems the patient unsuitable for MMAE-based ADC treatment.

  6. At least one per v1.1. (Lesions in previously irradiated areas are considered target lesions only if clear progression is documented after radiotherapy).
  7. Performance Status of 0 or 1 at screening.
  8. Expected survival > 3 months.
  9. Must have adequate organ and bone marrow function (no blood transfusion, growth factors, or albumin support within 14 days prior to screening):

    • Hematological: >= 1.5 x 10\^9/L; >= 75 x 10\^9/L; >= 90 g/L.
    • Hepatic: and AST \<= 2.5 x (or \<= 5 x ULN for patients with liver metastases); Total \<= 1.5 x ULN (if Total Bilirubin > 1.5 x ULN, Direct Bilirubin must be \<= ULN).
    • Coagulation: \<= 1.5; APTT \<= 1.5 x ULN; PT \< ULN + 4 seconds.
    • Renal: (CrCl) >= 30 mL/min, or Serum Creatinine \<= 1.5 x ULN.

Exclusion criteria

Exclusion Criteria

  1. Prior treatment with TROP2-targeted ADCs, topoisomerase I inhibitors (e.g., irinotecan, topotecan), or ADCs containing topoisomerase I inhibitor payloads.
  2. Patients previously treated with both Enfortumab Vedotin (EV) and Disitamab Vedotin (DV) are excluded from Cohorts A and B (eligible for Cohort C only).
  3. Treatment with any anti-tumor agents, chemotherapy, immunotherapy, monoclonal antibodies, targeted therapy, or radical radiotherapy within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose. Major surgery within 4 weeks prior to the first dose.
  4. Active CNS or meningeal . Patients with previously treated are eligible if clinically stable for ≥ 4 weeks, off systemic for ≥ 2 weeks (physiological replacement ≤ 10 mg/day prednisone equivalent is allowed), and no evidence of radiographic progression.
  5. History of non-infectious pneumonitis/interstitial lung disease (ILD) requiring steroids. Current ILD or suspected ILD on screening chest CT (even if asymptomatic). Severe , severely impaired lung function, or requirement for long-term oxygen therapy.
  6. interval > 470 ms (females) or > 450 ms (males). Within 6 months prior to the first dose: myocardial infarction, unstable angina, severe arrhythmia requiring intervention, uncontrolled hypertension, stroke, or . Class III or IV congestive heart failure.
  7. Active keratitis, corneal ulcer, or severe dry eye syndrome.
  8. Active (HBsAg positive and HBV-DNA > 2000 IU/mL; patients with lower HBV-DNA must receive antiviral therapy); Active (HCV antibody and RNA positive); Known infection; Severe infection requiring IV antibiotics within 2 weeks prior to first dose.
  9. : Known severe hypersensitivity to sac-TMT, EV, DV, or their .
  10. Any severe or uncontrolled systemic disease that, in the investigator's opinion, increases the risk to the participant.
  11. ≥ 8% (Patients with well-controlled blood glucose, fasting glucose ≤ 10 mmol/L, and investigator approval are eligible).
  12. History of stem cell transplant or solid organ transplant.
  13. Pregnant or breastfeeding females.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Experimental

    Patients receive sac-TMT (a Topo-I inhibitor-payload ADC) following failure of prior MMAE-based ADC therapy.

    Drug: Sacituzumab Tirumotecan

  • Active comparator
    Active Comparator

    Patients receive an alternative MMAE-based ADC regimen as sequential therapy following progression on or intolerance to prior MMAE-based ADC treatment.

    Drug: MMAE-based ADC

  • Other
    Observational

    An observational cohort for patients who discontinued prior MMAE-ADCs due to neurotoxicity.

    Drug: Sacituzumab Tirumotecan (Observational Cohort)

Interventions

  • 4.0 mg/kg intravenously administered on Day 1 every 2 weeks.

    Also known as: sac-TMT, SKB264, MK-2870

  • DrugMMAE-based ADC

    EV (Enfortumab Vedotin): 1.25 mg/kg administered intravenously on Days 1, 8, and 15 of every 4 weeks. DV (Disitamab Vedotin): 2.0 mg/kg administered intravenously on Day 1 of every 2 weeks.

    Also known as: EV, DV

  • DrugSacituzumab tirumotecanStudies of Sacituzumab tirumotecanSacituzumab tirumotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    4.0 mg/kg intravenously administered on Day 1 every 2 weeks.

    Also known as: sac-TMT, SKB264, MK-2870

This study also gives Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Peripheral Neuropathy Progression Rate (PNPR)

    The PNPR is defined as the proportion of participants who experience their first occurrence of treatment-emergent peripheral neurotoxicity of Grade 2 or higher from the time of randomization until the end of treatment. Neurotoxicity severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, a 5-point ordinal scale ranging from Grade 1 (mild; asymptomatic or mild symptoms, clinical or diagnostic observations only) to Grade 5 (death related to adverse event). Higher grades indicate worse outcomes (i.e., more severe neurotoxicity). The difference in PNPR between treatment arms will be analyzed using the Cochran-Mantel-Haenszel (CMH) test, adjusted for stratification factors specified in the protocol.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

Secondary outcomes

  1. Percent Change in NCS Parameters

    The NCS percentage change is calculated as the relative change in electrophysiological parameters from baseline to each post-baseline assessment. The formula used is: \[(Post-baseline Value - Baseline Value) / Baseline Value\] × 100%.

    Time frame: Baseline, and at protocol-specified time points (including the time of first occurrence of Grade ≥2 neurotoxicity symptoms) during the treatment period, up to approximately 24 months.

  2. Cumulative Neurotoxicity Burden (CNB)

    Cumulative Neurotoxicity Burden (CNB) quantifies total peripheral neurotoxicity exposure, incorporating both severity and duration. Neurotoxicity grades are assigned using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, a 5-point ordinal scale ranging from Grade 1 (mild) to Grade 5 (death); higher grades indicate worse outcomes. Two complementary CNB metrics are calculated: 1. Raw CNB: trapezoidal AUC of NCI-CTCAE grades plotted against time from randomization to end of treatment. Unit: grade-months. 2. Time-Standardized CNB (CNB-TS): Raw CNB divided by total observation duration, expressed as mean grade per unit time. CNB-TS = AUC / T(observation). This standardizes burden across participants with differing treatment durations. Higher values of both metrics indicate worse outcomes. Between-arm comparisons will use mixed-effects models adjusted for stratification factors.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

  3. Health-Related Quality of Life: EORTC QLQ-C30

    Health-related quality of life (HRQoL) is assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), a 30-item validated cancer- specific questionnaire comprising 5 functional scales (physical, role, emotional, cognitive, social functioning), 3 symptom scales (fatigue, nausea/vomiting, pain), 6 single-item symptom assessments, and a global health status/quality of life scale. All scores are linearly transformed to a 0-100 scale. For functional scales and the global health status/QoL scale, higher scores indicate better functioning or better quality of life (better outcomes). For symptom scales and single items, higher scores indicate a higher level of symptom burden (worse outcomes). Mean changes from baseline in EORTC QLQ-C30 subscale scores will be compared between treatment arms using a mixed-effects model for repeated measures (MMRM), adjusted for stratification factors.

    Time frame: From randomization up to the end of treatment (approximately 24 months), assessed at baseline and at protocol-specified time points.

  4. Chemotherapy-Induced Peripheral Neuropathy Symptoms: EORTC QLQ-CIPN20

    Patient-reported peripheral neuropathy symptoms are assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20-item module (EORTC QLQ-CIPN20), a validated 20-item instrument designed to specifically capture sensory, motor, and autonomic symptoms of chemotherapy-induced peripheral neuropathy. Items are rated on a 4-point Likert scale (1 = "Not at all" to 4 = "Very much"). Raw scores are linearly transformed to a 0-100 scale. Higher scores indicate a higher level of peripheral neuropathy symptom burden (worse outcomes). Mean changes from baseline in EORTC QLQ-CIPN20 sensory, motor, and autonomic subscale scores will be compared between treatment arms using a mixed-effects model for repeated measures (MMRM), adjusted for stratification factors.

    Time frame: From randomization up to the end of treatment (approximately 24 months), assessed at baseline and at protocol-specified time points.

  5. Objective Response Rate (ORR)

    The proportion of participants who achieve a Complete Response (CR) or Partial Response (PR) based on RECIST v1.1.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

  6. Disease Control Rate (DCR)

    The proportion of participants with CR, PR, or Stable Disease (SD) maintained for at least 6 weeks.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

  7. Progression-Free Survival (PFS)

    The time from randomization to the first disease progression (per RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

  8. Overall Survival (OS)

    The time from randomization to death from any cause.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

  9. Duration of Response (DoR)

    The time from the first documented CR or PR until the first documented disease progression or death.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

  10. Adverse Events (AEs)

    Assessment of AEs graded by NCI-CTCAE v5.0 including incidence, type, severity, duration, and relationship to study drug.

    Time frame: From randomization up to the end of treatment (approximately 24 months).

Other outcomes

  1. Serum Neurofilament Light Chain (sNfL) Levels

    Serum neurofilament light chain (sNfL) is a blood-based biomarker of neuronal axonal injury. Elevated sNfL levels reflect ongoing axonal damage and have been validated as a biomarker for chemotherapy-induced peripheral neuropathy and other neurodegenerative conditions. sNfL concentration is measured in serum using a quantitative single-molecule array (Simoa) immunoassay. Results are reported in picograms per milliliter (pg/mL). Higher sNfL levels indicate greater axonal injury (worse neurological outcomes). Outcomes assessed include: (1) absolute sNfL concentration at each time point, (2) change from baseline in sNfL concentration, and (3) fold change in sNfL from baseline. Between-arm comparisons will be performed using mixed-effects model for repeated measures (MMRM) on log-transformed values.

    Time frame: Baseline, and at protocol-specified time points during treatment (including the time of first occurrence of Grade ≥2 neurotoxicity symptoms), up to approximately 24 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2028, 28 months later.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's planned 28 months is below that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2026
First posted
Jun 23, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2029
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662863
Lead sponsor
Fudan University
Responsible party
Ding-Wei Ye (Professor, Fudan University) — Principal investigator
First posted
Jun 23, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Jun 23, 2026

Study contacts

Yao Zhu
Contact
zhuyao@fudan.edu.cn
+86 13816751347
Shanshan Wang
Contact
fuscc_wangshanshan@fudan.edu.cn
+86 13918029242

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion